Mavodelpar

Mavodelpar (REN001) is a selective PPARδ agonist. Mavodelpar suppresses glomerular injury and renal fibrosis. Mavodelpar can be used for the research of primary mitochondrial myopathies (PMM) and long-chain fatty acid oxidation disorders (LC-FAOD)[1].

Signaling Pathways >> Cell Cycle/DNA Damage >> PPAR

Research Areas >> Inflammation/Immunology

Mavodelpar (10 mg/kg；腹腔注射，10 mg/kg，每日 1 次，6-17 周龄) 可有效抑制肾小球损伤和肾纤维化，并降低纤维化相关蛋白的水平[1]。 Animal Model: Male and female B6129SF1-Col4a3-/- mice[1] Dosage: 10 mg/kg Administration: Intraperitoneal injection; 10 mg/kg, once daily, from 6 to 17 weeks of age Result: Suppressed proteinuria and blood urea nitrogen (BUN) levels. Reduced glomerular injury, renal fibrosis, phosho-Stat3 and connective tissue growth factor (CTGF) levels. Decreased the expression level of the activated fibroblast marker alpha-SMA and Collagen I and IV.

[1]. Omachi K, et al. PPARδ agonism ameliorates renal fibrosis in an Alport syndrome mouse model. Kidney360. 2022 Nov 29.